Article information
Full text is only aviable in PDF
References
[1.]
K. Kannan, R.A. Ortmann, D. Kimpel.
Animal models of rheumatoid arthritis and their relevance to human disease.
Pathophysiology, 12 (2005), pp. 167-181
[2.]
R.O. Williams.
Rodent models of arthritis: relevance for human disease.
Clin Exp Immunol, 114 (1998), pp. 330-332
[3.]
S. Sakaguchi, N. Sakaguchi.
Animal models of arthritis caused by systemic alteration of the immune system.
Curr Opin Immunol, 17 (2005), pp. 589-594
[4.]
R.O. Williams.
Collagen-induced arthritis as a model for rheumatoid arthritis.
Methods Mol Med, 98 (2004), pp. 207-216
[5.]
K.S. Nandakumar, R. Holmdahl.
Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis.
Arthritis Res Ther, 8 (2006), pp. 223-234
[6.]
D. Kyburz, M. Corr.
The KRN mouse model of inflammatory arthritis.
Springer Semin Immunopathol, 25 (2003), pp. 79-90
[7.]
P. Li, E.M. Schwarz.
The TNF-alpha transgenic mouse model of inflammatory arthritis.
Springer Semin Immunopathol, 25 (2003), pp. 19-33
[8.]
Y. Niki, H. Yamada, S. Seki, T. Kikuchi, H. Takaishi, Y. Toyama, et al.
Macrophage- and neutrophil-dominant arthritis in human IL-1 alpha transgenic mice.
J Clin Invest, 107 (2001), pp. 1127-1135
[9.]
P.H. Wooley.
The usefulness and the limitations of animal models in identifying targets for therapy in arthritis.
Best Pract Res Clin Rheumatol, 18 (2004), pp. 47-58
[10.]
B.A. ‘t Hart, S. Amor, M. Jonker.
Evaluating the validity of animal models for research into therapies for immune-based disorders.
Drug Discov Today, 9 (2004), pp. 517-524
[11.]
H.A. Arnett, J.L. Viney.
Considerations for the sensible use of rodent models of inflammatory disease in predicting efficacy of new biological therapeutics in the clinic.
Adv Drug Deliv Rev, 59 (2007), pp. 1084-1092
[12.]
M. Hegen, J.C. Keith Jr., M. Collins, C.L. Nickerson-Nutter.
Utility of animal models for identification of potential therapeutics for Rheumatoid Arthritis.
Ann Rheum Dis., (2007),
[13.]
W.B. van der Berg.
Arguments for IL-1 as a target in chronic arthritis.
Ann Rheum Dis, 59 (2000), pp. i81-i84
[14.]
G. Horneff, G.R. Burmester, F. Emmrich, J.R. Kalden.
Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody.
Arthritis Rheum, 34 (1991), pp. 129-140
[15.]
P.C. Taylor.
Antibody therapy for rheumatoid arthritis.
Curr Opin Pharmacol, 3 (2003), pp. 323-328
[16.]
R.O. Williams, M. Feldmann, R.N. Maini.
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.
Proc Natl Acad Sci USA, 89 (1992), pp. 9784-9788
[17.]
D.L. Scott, G.H. Kingsley.
Tumor necrosis factor inhibitors for rheumatoid arthritis.
N Engl J Med, 355 (2006), pp. 704-712
[18.]
D.B. Knoerzer, R.W. Karr, B.D. Schwartz, L.J. Mengle-Gaw.
Collagen-induced arthritis in the BB rat.
Prevention of disease by treatment with CTLA-4- Ig. J Clin Invest, 96 (1995), pp. 987-993
[19.]
J.M. Kremer, M. Dougados, P. Emery, P. Durez, J. Sibilia, W. Shergy.
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebocontrolled trial.
Arthritis Rheum, 52 (2005), pp. 2263-2271
[20.]
K. Dunussi-Joannopoulos, G.E. Hancock, A. Kunz, M. Hegen, X.X. Zhou, B.J. Sheppard, et al.
B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model.
Blood, 106 (2005), pp. 2235-2243
[21.]
J.C. Edwards, L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D.R. Close, et al.
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
N Engl J Med, 350 (2004), pp. 2572-2581
[22.]
T. Alonzi, E. Fattori, D. Lazzaro, P. Costa, L. Probert, G. Kollias, et al.
Interleukin 6 is required for the development of collagen-induced arthritis.
J Exp Med, 187 (1998), pp. 461-468
[23.]
R.N. Maini, P.C. Taylor, J. Szechinski, K. Pavelka, J. Bröll, G. Balint, et al.
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.
Arthritis Rheum, 54 (2006), pp. 2817-2829
[24.]
N. Nishimoto, K. Yoshizaki, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, et al.
Treatment of rheumatoid arthritis with humanized anti-interleukin- 6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.
Arthritis Rheum, 50 (2004), pp. 1761-1769
[25.]
P.R. Pine, B. Chang, N. Schoettler, M.L. Banquerigo, S. Wang, A. Lau, et al.
Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.
Clin Immunol, 124 (2007), pp. 244-257
[26.]
S.E. Sweeney, G.S. Firestein.
Mitogen activated protein kinase inhibitors: where are we now and where are we going?.
Ann Rheum Dis, 65 (2006), pp. iii83-iii88
Copyright © 2008. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
